Sei Investments Co. Lowers Holdings in Repligen Co. (NASDAQ:RGEN)

Sei Investments Co. cut its holdings in Repligen Co. (NASDAQ:RGEN) by 15.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 218,714 shares of the biotechnology company’s stock after selling 40,227 shares during the period. Sei Investments Co.’s holdings in Repligen were worth $40,226,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in RGEN. YHB Investment Advisors Inc. purchased a new position in Repligen in the 1st quarter worth approximately $26,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 146 shares in the last quarter. Principal Securities Inc. purchased a new stake in shares of Repligen during the 4th quarter worth approximately $48,000. CWM LLC raised its holdings in shares of Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 60 shares in the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Repligen by 48.4% during the 4th quarter. Signaturefd LLC now owns 417 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 136 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised Repligen from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. JPMorgan Chase & Co. decreased their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Finally, Guggenheim assumed coverage on Repligen in a report on Tuesday, June 18th. They set a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $193.00.

Repligen Trading Down 2.6 %

NASDAQ:RGEN traded down $3.32 during midday trading on Monday, hitting $122.60. 518,438 shares of the company traded hands, compared to its average volume of 594,715. The firm’s fifty day moving average is $143.06 and its 200-day moving average is $169.73. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The firm has a market capitalization of $6.85 billion, a P/E ratio of 490.70, a P/E/G ratio of 4.21 and a beta of 0.96. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter in the previous year, the company posted $0.64 EPS. The business’s quarterly revenue was down 17.1% on a year-over-year basis. On average, sell-side analysts predict that Repligen Co. will post 1.46 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, CEO Anthony Hunt bought 2,000 shares of Repligen stock in a transaction on Friday, June 14th. The shares were acquired at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the completion of the purchase, the chief executive officer now directly owns 165,177 shares in the company, valued at approximately $20,495,162.16. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Martin D. Madaus purchased 1,615 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were purchased at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the purchase, the director now owns 4,613 shares in the company, valued at approximately $576,348.22. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Anthony Hunt purchased 2,000 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were purchased at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the purchase, the chief executive officer now owns 165,177 shares of the company’s stock, valued at approximately $20,495,162.16. The disclosure for this purchase can be found here. Insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.